Retina is a layer of nerve tissue lining the back of the eye. Retina receives light and convert it into neural signals, and send these signals to the brain for visual recognition. The central part of the retina is known as macula, which is responsible for central vision. The remaining tissue outside the macula is responsible for peripheral vision. There are many types of retinal diseases.
View Report –
Some of these diseases involve only the macula such as age-related macular degeneration, macular pucker (epiretinal membrane), or macular hole; other diseases can impact the entire retina such as retinal detachment or diabetic retinopathy. The treatment of retinal diseases ranges from administration of eye drops to surgical procedures such as laser therapy, vitreoretinal surgery, and intraocular injection. All these procedures are aimed to preserve the integrity of the retina.
There is an alarming rise in the incidence of eye-related diseases, especially in developed countries, which in turn is anticipated to drive the growth of the global retinal drugs market during the forecast period. According to an update from the American Academy of Ophthalmology in 2016, about 93 million people had diabetic retinopathy worldwide, of which 4.2 million patients were from the U.S. Increasing health education initiatives about eye diseases to seek early treatment and prevent visual impairment in emerging regions are further anticipated to fuel the expansion of the global market for retinal drugs during the forecast period.
Request to View Brochure of Report –
Several initiatives have been undertaken across the globe to spread awareness about diagnosis and treatment methods of ophthalmic diseases. The International Centre for Eye Health focuses on increasing awareness about eye health problems and treatment. The World Glaucoma Association has been arranging World Glaucoma Congress for the past six years to increase awareness and discussion about glaucoma treatment advancements. Macular Degeneration Association, Inc. arranges seminars every month across various places to increase treatment penetration for age-related macular degeneration (AMD). These initiatives are expected to increase the adoption of various treatment methods which in turn is projected to fuel the growth of the market.
The global market for retinal drugs has been segmented on the basis of retinal disorder, distribution channel, and region. On the basis of retinal disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole, and others. In terms of distribution channel, the market is categorized into hospital pharmacies, online pharmacies, and independent pharmacies and drug stores. On the basis of region, the global retinal drugs market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The global retinal drugs market is highly fragmented due to the participation of many global as well as new players. Major players operating in the market are Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., Shire Plc, Bayer AG, Novartis International AG, Valeant Pharmaceuticals International, Inc., and Merck & Co., Inc.
Comments
Post a Comment